123 related articles for article (PubMed ID: 35494973)
1. Feasibility, Tolerance, and Quality of Life for Hypofractionation Versus Conventional Fractionation for Post-mastectomy Radiotherapy in Indian Patients.
Malik D; Singh A; Birajdar MM; Vyas VJ
Cureus; 2022 Mar; 14(3):e23497. PubMed ID: 35494973
[TBL] [Abstract][Full Text] [Related]
2. Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer.
Jain N; Sharma R; Sachdeva K; Kaur A; Sudan M
J Med Phys; 2022; 47(2):141-144. PubMed ID: 36212213
[TBL] [Abstract][Full Text] [Related]
3. A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis.
Gil GOB; de Andrade WP; Diniz PHC; Cantidio FS; Queiroz IN; Gil MLBV; Almeida CAM; Caldeira PPR; Regalin M; Silva-Filho AL
Front Oncol; 2023; 13():1202544. PubMed ID: 37388233
[TBL] [Abstract][Full Text] [Related]
4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
5. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trial.
Yadav BS; Dahiya D; Gupta M; Gupta A; Oinam AS; Khare S; Irrinki S; Robert N; Sakaray YR; Nagaraj SS; Kumari R
Lancet Reg Health Southeast Asia; 2024 May; 24():100392. PubMed ID: 38550605
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India.
Nandi M; Mahata A; Mallick I; Achari R; Chatterjee S
Asian Pac J Cancer Prev; 2014; 15(6):2505-10. PubMed ID: 24761855
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
10. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.
Hopwood P; Haviland JS; Sumo G; Mills J; Bliss JM; Yarnold JR;
Lancet Oncol; 2010 Mar; 11(3):231-40. PubMed ID: 20138809
[TBL] [Abstract][Full Text] [Related]
11. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy.
Versmessen H; Vinh-Hung V; Van Parijs H; Miedema G; Voordeckers M; Adriaenssens N; Storme G; De Ridder M
BMC Cancer; 2012 Oct; 12():495. PubMed ID: 23098579
[TBL] [Abstract][Full Text] [Related]
14. Accelerated hypofractionated radiotherapy as adjuvant regimen after conserving surgery for early breast cancer: interim report of toxicity after a minimum follow up of 3 years.
Pinnarò P; Soriani A; Landoni V; Giordano C; Papale M; Marsella A; Marucci L; Arcangeli G; Strigari L
J Exp Clin Cancer Res; 2010 Jan; 29(1):9. PubMed ID: 20100335
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial.
Chatterjee S; Chakraborty S;
Trials; 2020 Sep; 21(1):819. PubMed ID: 32998747
[TBL] [Abstract][Full Text] [Related]
16. Late-term effects of hypofractionated chest wall and regional nodal radiotherapy with two-dimensional technique in patients with breast cancer.
Yadav BS; Bansal A; Kuttikat PG; Das D; Gupta A; Dahiya D
Radiat Oncol J; 2020 Jun; 38(2):109-118. PubMed ID: 33012154
[TBL] [Abstract][Full Text] [Related]
17. Differences in the Acute Toxic Effects of Breast Radiotherapy by Fractionation Schedule: Comparative Analysis of Physician-Assessed and Patient-Reported Outcomes in a Large Multicenter Cohort.
Jagsi R; Griffith KA; Boike TP; Walker E; Nurushev T; Grills IS; Moran JM; Feng M; Hayman J; Pierce LJ
JAMA Oncol; 2015 Oct; 1(7):918-30. PubMed ID: 26247417
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
Jiang H; Meng L; Zhang H; Dai X; Zhang Q; Ju Z; Yu W; Ma L
BMC Cancer; 2021 Dec; 21(1):1284. PubMed ID: 34852776
[TBL] [Abstract][Full Text] [Related]
19. Assessment of acute toxicities and early local recurrences in post mastectomy breast cancer patients by accelerated hypofractionated radiotherapy; a single arm clinical trial.
Vijayaraghavan N; Vedasoundaram P; M Mathew J; Menon A; Kannan B
J BUON; 2020; 25(5):2265-2270. PubMed ID: 33277844
[TBL] [Abstract][Full Text] [Related]
20. Acute radiation-induced skin toxicity in hypofractionated vs. conventional whole-breast irradiation: An objective, randomized multicenter assessment using spectrophotometry.
Schmeel LC; Koch D; Schmeel FC; Röhner F; Schoroth F; Bücheler BM; Mahlmann B; Leitzen C; Schüller H; Tschirner S; Fuhrmann A; Heimann M; Brüser D; Abramian AV; Müdder T; Garbe S; Vornholt S; Schild HH; Baumert BG; Wilhelm-Buchstab TM
Radiother Oncol; 2020 May; 146():172-179. PubMed ID: 32171945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
